General descriptionCWR-R1ca is a fibroblast-free cell line derived from the castration-resistant or recurrent CWR-R1 human prostate cancer cell line (1). Removal of fibroblasts from the original parental CWR-R1 cells was accomplished by multiple cycles of short-term trypsinization, cloning and pooling single-cell colonies (1). CWR-R1ca cells express AR-FL, and its splice variant AR-V7, CK-8, CK-18 and c-Met and are highly responsive to androgen for growth (1).
Key Applications:
• Androgen Receptor Splice Variant 7 (AR-V7) studies
• Anti-androgen therapy
• In vivo tumorigenesis
Prostate cancer is a leading cause of male cancer mortality. The androgen receptor (AR) is important for normal development and maintenance of the prostate and is also critical for the survival and progression of prostate cancer. Current treatment of advanced or metastatic prostate cancer relies on androgen deprivation by inhibiting androgen synthesis or anti-androgens that bind to the AR ligand binding domain. The initial response to androgen deprivation therapy is favorable, however, most patients inevitably relapse to a more aggressive, castration-resistant prostate cancer (CRPC), caused by continued transactivation of AR.
CWR-R1ca was derived from the castration-resistant or recurrent CWR-R1 human prostate cancer cell line . The original parental CWR-R1 is a human prostate carcinoma epithelial cell line derived from the recurrent CWR22 human xenograft tumors that were harvested from nude mice 140-160 days after castration and express AR full length (AR-FL), AR-V7 and PSA mRNA and protein .
ApplicationResearch Category
Cancer
Oncology
Subject to local law, this product is intended to be sold for internal in vitro research use only subject to terms and conditions found here: www.sigmaaldrich.com/restrictedcelluse. This product may not be: re-engineered or copied; used to make derivatives, modifications or functional equivalents; used to obtain patents or other IP claiming use of the product; used to develop, test, or manufacturer a commercial product; used as a component in a commercial product; resold or licensed; used in any clinical applications or trials; or used in humans. A license or limited commercial use agreement is required for use by any for-profit entity, use in services, and use in sponsored academic research. For information regarding any such use, please contact
[email protected].
Biochem/physiol ActionsCancer Cells
Preparation NoteStore in liquid nitrogen. The cells can be cultured for at least 10 passages after initial thawing without significantly affecting the cell marker expression and functionality.
Analysis Note• Each vial contains ≥ 1X10⁶ viable cells.
• Cells are tested by PCR and are negative for HPV-16, HPV-18, Hepatitis A, B, C and HIV-1 & 2 viruses.
• Cells are negative for mycoplasma contamination.
• Each lot of cells are genotyped by STR analysis to verify the unique identity of the cell line.
DisclaimerRESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
